Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

AIM: To perform a model‐based analysis of the short‐ and long‐term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden. MATERIALS AND METHODS: The validated Institute for Health Economi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nilsson, Kristoffer, Andersson, Emelie, Persson, Sofie, Karlsdotter, Kristina, Skogsberg, Josefin, Gustavsson, Staffan, Jendle, Johan, Steen Carlsson, Katarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107920/
https://www.ncbi.nlm.nih.gov/pubmed/36371543
http://dx.doi.org/10.1111/dom.14921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107920/
https://www.ncbi.nlm.nih.gov/pubmed/36371543
http://dx.doi.org/10.1111/dom.14921

Ejemplares similares